These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34661454)

  • 1. Ripretinib for advanced gastrointestinal stromal tumor: Plain language summary of the INVICTUS study.
    Symcox M; Somaiah N
    Future Oncol; 2021 Dec; 17(36):5007-5012. PubMed ID: 34661454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.
    Symcox M; Jones RL
    Future Oncol; 2023 Nov; 19(36):2383-2393. PubMed ID: 37594164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
    Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
    Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ripretinib in treatment of repeatedly relapsing rectal gastrointestinal stromal tumor: a case report.
    Wu C; Zhang J; Wu X
    Ann Palliat Med; 2021 Apr; 10(4):4994-4998. PubMed ID: 33966435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy.
    Fung S; Shirley M
    Drugs; 2022 Oct; 82(15):1541-1548. PubMed ID: 36282417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour.
    George S; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Razak AA; Gordon MS; Somaiah N; Jennings J; Meade J; Shi K; Su Y; Ruiz-Soto R; Janku F
    Eur J Cancer; 2021 Sep; 155():236-244. PubMed ID: 34391056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
    Zalcberg JR; Heinrich MC; George S; Bauer S; Schöffski P; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Somaiah N; Meade J; Reichert V; Shi K; Sherman ML; Ruiz-Soto R; von Mehren M; Blay JY
    Oncologist; 2021 Nov; 26(11):e2053-e2060. PubMed ID: 34313371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
    Janku F; Abdul Razak AR; Chi P; Heinrich MC; von Mehren M; Jones RL; Ganjoo K; Trent J; Gelderblom H; Somaiah N; Hu S; Rosen O; Su Y; Ruiz-Soto R; Gordon M; George S
    J Clin Oncol; 2020 Oct; 38(28):3294-3303. PubMed ID: 32804590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial.
    Schöffski P; George S; Heinrich MC; Zalcberg JR; Bauer S; Gelderblom H; Serrano C; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Becker C; Shi K; Meade J; Ruiz-Soto R; Blay JY; von Mehren M
    BMC Cancer; 2022 Dec; 22(1):1302. PubMed ID: 36514034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ripretinib (Qinlock) for GIST.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
    [No Abstract]   [Full Text] [Related]  

  • 12. Ripretinib for the treatment of adult patients with advanced gastrointestinal stromal tumors.
    Sargsyan A; Kucharczyk MA; Jones RL; Constantinidou A
    Expert Rev Gastroenterol Hepatol; 2023 Feb; 17(2):119-127. PubMed ID: 36644853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
    Kumar V; Doros L; Thompson M; Mushti SL; Charlab R; Spehalski EI; Zhao H; Thompson MD; Tang S; Pazdur R; Lemery SJ; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Jun; 29(11):2020-2024. PubMed ID: 36485007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New drug approvals: Ripretinib for advanced gastrointestinal stromal tumors (GIST) in fourth or later-line therapy].
    Lemaître J; Watson S
    Bull Cancer; 2022 Mar; 109(3):250-252. PubMed ID: 35094842
    [No Abstract]   [Full Text] [Related]  

  • 15. USP5 Promotes Ripretinib Resistance in Gastrointestinal Stromal Tumors by MDH2 Deubiquition.
    Sun H; Cui Z; Li C; Gao Z; Xu J; Bian Y; Gu T; Zhang J; Li T; Zhou Q; Yang D; He Z; Li B; Li F; Xu Z; Xu H
    Adv Sci (Weinh); 2024 Sep; 11(34):e2401171. PubMed ID: 38973363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study.
    Li J; Cai S; Zhou Y; Zhang J; Zhou Y; Cao H; Wu X; Deng Y; Huang Z; Dong J; Shen L
    Clin Cancer Res; 2022 Aug; 28(16):3425-3432. PubMed ID: 35686969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ripretinib in Chinese patients with advanced gastrointestinal stromal tumors: a real-world, multicenter, observational study.
    Yang W; Qian H; Yang L; Wang P; Qian H; Chu B; Liu Z; Sun J; Wu D; Sun L; Zhou W; Hu J; Chen X; Shou C; Ruan L; Zhang Y; Yu J
    Front Oncol; 2023; 13():1180795. PubMed ID: 37274264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience.
    Lin LC; Huang WK; Yen CC; Yang CY; Sung MT; Wong NS; Chua DTT; Lee SWM; Chen JS; Yeh CN
    Front Oncol; 2022; 12():883399. PubMed ID: 35847924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ripretinib: First Approval.
    Dhillon S
    Drugs; 2020 Jul; 80(11):1133-1138. PubMed ID: 32578014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors.
    Liao W; Xu H; Hutton D; Wu Q; Zhou K; Luo H; Lei W; Feng M; Yang Y; Wen F; Li Q
    Front Oncol; 2021; 11():692005. PubMed ID: 34938653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.